Lupin Gets USFDA Diazepam Injection Approval in 2026

Key update from Lupin’s US regulatory pipeline

Lupin Limited has announced final regulatory clearance in the United States for Diazepam Injection, USP, adding another injectable product to its US portfolio. The update was disclosed as part of the company’s announcements under Regulation 30 (LODR), alongside other US milestones that include a commercial launch and additional approvals. The development matters because USFDA approvals directly expand addressable opportunities for Indian drugmakers in a market where injectable supply reliability and approved formats can influence adoption. Lupin also positioned the Diazepam approval within a broader set of filings and inspections, indicating continued focus on the US generics pipeline.

USFDA approval: product, strength, and format

Lupin said it has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Diazepam Injection, USP. The approved strength is 10 mg/2 mL (5 mg/mL). The product is packaged as single-dose prefilled syringes, which is the specific configuration cleared by the regulator. The company stated that the approval is under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Bioequivalence reference: Valium Injection

According to Lupin’s regulatory update, the USFDA has approved Lupin’s Diazepam Injection as bioequivalent to the reference listed drug (RLD) Valium Injection 10 mg/2 mL (5 mg/mL). The RLD is from Hoffmann-La Roche Inc. By referencing bioequivalence to the RLD, the filing is positioned within the standard US generic drug pathway via ANDA. Lupin’s disclosure focused on the final approval status and did not cite any pricing or launch-date specifics for Diazepam Injection in the US.

Indication mentioned in the filing

Lupin said the approved Diazepam Injection is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. The company’s note links the product’s medical use to the labeling associated with the approved reference product. Lupin’s statement did not add additional indications beyond what was specified in the update. No patient or prescriber guidance was detailed in the disclosed text, beyond the broad indication.

Market size referenced for the US opportunity

The market update accompanying the approval described Diazepam Injection as targeting a US market with estimated annual sales of USD 77.9 million. This figure was presented as an annual sales size estimate for the US market. Lupin did not provide its own projected revenue share, volume expectations, or timing assumptions tied to this market size. The company also did not specify how many competitors currently operate in this segment in the disclosed text.

Parallel US milestone: Sugammadex Injection launch

Alongside the Diazepam approval, Lupin also stated it has commercially launched Sugammadex Injection in the United States. The announcement positioned the launch and the Diazepam final approval as two major US regulatory milestones, combining an already-commercial product update with a newly approved injectable. The provided text did not include strengths, therapeutic area details, or market-size figures for Sugammadex. It also did not disclose launch partners or distribution arrangements.

Manufacturing and compliance: Aurangabad facility EIR

Lupin also disclosed it has received an Establishment Inspection Report (EIR) from the USFDA for its Aurangabad facility. The company said this EIR follows a product-specific pre-approval inspection conducted in September. While the filing did not link the EIR to a specific product name in the excerpt, the disclosure is relevant because inspection outcomes can influence US filing and approval timelines. Lupin’s update did not state any further observations, remediation actions, or next inspection dates.

Other regulatory updates: tentative approvals in the pipeline

In another update included in the same information set, Lupin said it has received tentative approval from the USFDA for its ANDA for bictegravir, emtricitabine, and tenofovir alafenamide tablets (50 mg/200 mg/25 mg). The disclosure referred to this as an HIV treatment tablet combination. Separately, Lupin also announced tentative approval for Enzalutamide Tablets, with strengths listed as 40 mg, 80 mg, 120 mg, and 160 mg. The company stated the USFDA has tentatively approved its 40 mg and 80 mg strengths as bioequivalent to the reference listed drug Xtandi tablets of Astellas, for the indication in the approved labeling.

Context from earlier approval: Tolvaptan ANDA clearance

The disclosed text also referenced Lupin’s earlier USFDA approval (dated April 24, 2025) for its ANDA for Tolvaptan Tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. Lupin stated the product is bioequivalent to Jynarque Tablets of Otsuka Pharmaceutical Company. The company added that it holds exclusive first-to-file status for this product and is eligible for 180 days of generic drug exclusivity. Lupin also said the product will be manufactured at its Nagpur facility in India and will be launched soon, without specifying an exact date.

Summary table: what Lupin disclosed

Market impact: what the update signals

For Lupin, the Diazepam final approval adds another US-approved product in an injectable presentation, and the company has highlighted a clear reference market size estimate of USD 77.9 million annually. The same update bundle also points to ongoing US-facing execution across multiple fronts: commercialisation (Sugammadex), regulatory progress (tentative approvals), and compliance visibility (EIR for Aurangabad). However, the disclosure does not quantify expected revenue contribution, margin impact, or product-specific launch timing for Diazepam. Investors typically track such updates because they reflect the pace of additions to the US portfolio and the regulatory standing of manufacturing sites supporting that portfolio.

Analysis: why Diazepam prefilled syringes matter in a filing

The specificity of the approved format (single-dose prefilled syringes) is notable because it defines exactly what Lupin can supply under the approved ANDA. The company also anchored its approval to bioequivalence with a widely recognised reference listed product, which is central to generic adoption pathways in the US. Within Lupin’s broader US announcements, Diazepam sits alongside products at different stages: final approvals, tentative approvals, and manufacturing-readiness updates. This combination indicates a pipeline approach rather than a single-product event, with multiple potential levers for US growth if launches and supply execution follow the approvals.

Conclusion

Lupin’s USFDA approval for Diazepam Injection, USP (10 mg/2 mL) in single-dose prefilled syringes strengthens its US injectable portfolio and targets a reported USD 77.9 million annual US market. The company has paired the update with a Sugammadex launch, an EIR for its Aurangabad facility, and additional tentative approvals across therapies. Further clarity for investors is likely to come from any future disclosures on Diazepam launch timing, commercial ramp-up, and additional US pipeline decisions.